DEPARTMENT OF HEALTH & HUMAN SERVICES

Centers for Medicare & Medicaid Services 601 E. 12th St., Room 355 Kansas City, Missouri 64106



Medicaid and CHIP Operations Group

May 10, 2022

Susan Birch, Director Dr. Charissa Fotinos, Acting Medicaid Director Health Care Authority PO Box 45502 Olympia, WA 98504-5010

Re: Washington State Plan Amendment (SPA) Transmittal Number WA-22-0008

Dear Dr. Fotinos and Susan Birch:

The Centers for Medicare & Medicaid Services (CMS) reviewed your Medicaid State Plan Amendment (SPA) submitted under transmittal number (TN) WA-22-0008. This amendment was submitted to comply with coverage of routine patient costs for services and items provided to Medicaid beneficiaries in connection with participation in qualifying clinic trials, in accordance with the federal 2021 Consolidated Appropriations Act (CAA).

We conducted our review of your submittal according to statutory requirements in Title XIX of the Social Security Act and implementing regulations 1905(a), 1905(gg) of the Act. This letter is to inform you that Washington Medicaid SPA 22-0008 was approved on May 10, 2022 with an effective date of January 1, 2022.

If you have any questions, please contact Edwin Walaszek at 212-616-2512 or via email at Edwin.Walaszek1@cms.hhs.gov.

Sincerely,

James G. Scott, Director Division of Program Operations

cc: Ann Myers-ann.myers@hca.wa.gov

CENTERO I ON MEDIOVICE & MEDIOVID CENTROLO	4 TRANCAUTTAL AUGARER	IO CTATE
TRANSMITTAL AND NOTICE OF APPROVAL OF STATE PLAN MATERIAL	1. TRANSMITTAL NUMBER	2. STATE
FOR: CENTERS FOR MEDICARE & MEDICAID SERVICES	3. PROGRAM IDENTIFICATION: TITLE OF	F THE SOCIAL
	SECURITY ACT XIX	XXI
TO: CENTER DIRECTOR	4. PROPOSED EFFECTIVE DATE	, , , ,
CENTERS FOR MEDICAID & CHIP SERVICES	4. THOI COLD ELLE CHIVE DATE	
DEPARTMENT OF HEALTH AND HUMAN SERVICES	LO SERENAL BURGET MARA OT (A	(: \\(\)
5. FEDERAL STATUTE/REGULATION CITATION	6. FEDERAL BUDGET IMPACT (Amou a. FFY\$\$	nts in WHOLE dollars)
	b. FFY\$	
7. PAGE NUMBER OF THE PLAN SECTION OR ATTACHMENT	8. PAGE NUMBER OF THE SUPERSEI OR ATTACHMENT (If Applicable)	DED PLAN SECTION
9. SUBJECT OF AMENDMENT		
10. GOVERNOR'S REVIEW (Check One)		
GOVERNOR'S OFFICE REPORTED NO COMMENT COMMENTS OF GOVERNOR'S OFFICE ENCLOSED NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL	OTHER, AS SPECIFIED: Exem	pt
11. SIGNATURE OF STATE AGENCY OFFICIAL 15 15 16 17 18 19 19 19 19 19 19 19 19 19	. RETURN TO	
12. TYPED NAME		
13. TITLE		
14. DATE SUBMITTED		
FOR CMS USE	EONLY	
	. DATE APPROVED	
March 8, 2022	May 10, 2022	
PLAN APPROVED - ONE		
18. EFFECTIVE DATE OF APPROVED MATERIAL 1/1/22	. SIGNATURE OF APPROVING OFFICIA	AL
20. TYPED NAME OF APPROVING OFFICIAL 21	. TITLE OF APPROVING OFFICIAL	
James G. Scott	Director, Division of Pro	ogram Operations
22. REMARKS		

Effective Date: 1/1/2022

STATE PLAN UNDER TITLE XIX OF THE SOCIAL SECURITY ACT

State	WASHINGTON	

AMOUNT, DURATION, AND SCOPE OF MEDICAL AND REMEDIAL CARE AND SERVICES PROVIDED TO THE CATEGORICALLY NEEDY

30. Coverage of Routine Patient Cost in Qualifying Clinical Trials

*The state needs to check each assurance below.

Provided: __X__

I. General Assurances:

Routine Patient Cost - Section 1905(gg)(1)

__X_ Coverage of routine patient cost for items and services as defined in section 1905(gg)(1) that are furnished in connection with participation in a qualified clinical trial.

Qualifying Clinical Trial - Section 1905(gg)(2)

__X_ A qualified clinical trial is a clinical trial that meets the definition at section 1905(gg)(2).

Coverage Determination - Section 1905(gg)(3)

__X_ A determination with respect to coverage for an individual participating in a qualified clinical trial will be made in accordance with section 1905(gg)(3).

PRA Disclosure Statement - This information is being collected to assist the Centers for Medicare & Medicaid Services in implementing Section 210 of the Consolidated Appropriations Act of 2021 amending section 1905(a) of the Social Security Act (the Act), by adding a new mandatory benefit at section 1905(a)(30). Section 210 mandates coverage of routine patient services and costs furnished in connection with participation by Medicaid beneficiaries in qualifying clinical trials effective January 1, 2022. Section 210 also amended sections 1902(a)(10)(A) and 1937(b)(5) of the Act to make coverage of this new benefit mandatory under the state plan and any benchmark or benchmark equivalent coverage (also referred to as alternative benefit plans, or ABPs). Under the Privacy Act of 1974 any personally identifying information obtained will be kept private to the extent of the law. An agency may notconduct or sponsor, and a person is not required to respond to, a collection of information unlessit displays a currently valid Office of Management and Budget (OMB) control number. The OMB control number for this project is 0938-1148 (CMS-10398 #74). Public burden for all of the collection of information requirements under this control number is estimated to take about 56 hours per response. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to CMS, 7500 SecurityBoulevard, Attn: Paperwork Reduction Act Reports Clearance Officer, Mail Stop C4-26-05, Baltimore, Maryland 21244-1850.

Approval Date: 5/10/2022

Effective Date: 1/1/2022

STATE PLAN UNDER TITLE XIX OF THE SOCIAL SECURITY ACT

StateW	ASHINGTON
	TION, AND SCOPE OF SERVICES PROVIDED TO THE NEEDY GROUP(S):ALL
30. Coverage of Routine Patient Cos	st in Qualifying Clinical Trials
*The state needs to check each assu	urance below.
Provided: X	
II. General Assurances:	
Routine Patient Cost – Section 19	05(gg)(1)
_X_Coverage of routine patient cost in connection with participation in a c	for items and services as defined in section 1905(gg)(1) that are furnished qualified clinical trial.
Qualifying Clinical Trial – Section	1905(gg)(2)
X_A qualified clinical trial is a clinical	al trial that meets the definition at section 1905(gg)(2).
Coverage Determination – Section	າ 1905(gg)(3)
X A determination with respect to made in accordance with section 190	coverage for an individual participating in a qualified clinical trial will be 05(gg)(3).

PRA Disclosure Statement - This information is being collected to assist the Centers for Medicare & Medicaid Services in implementing Section 210 of the Consolidated Appropriations Act of 2021 amending section 1905(a) of the Social Security Act (the Act), by adding a new mandatory benefit at section 1905(a)(30). Section 210 mandates coverage of routine patient services and costs furnished in connection with participation by Medicaid beneficiaries in qualifying clinical trials effective January 1, 2022. Section 210 also amended sections 1902(a)(10)(A) and 1937(b)(5) of the Act to make coverage of this new benefit mandatory under the state plan and any benchmark or benchmark equivalent coverage (also referred to as alternative benefit plans, or ABPs). Under the Privacy Act of 1974 any personally identifying information obtained will be kept private to the extent of the law. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid Office of Management and Budget (OMB) control number. The OMB control number for this project is 0938-1148 (CMS-10398 #74). Public burden for all of the collection of information requirements under this control number is estimated to take about 56 hours per response. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to CMS, 7500 Security Boulevard, Attn: Paperwork Reduction Act Reports Clearance Officer, Mail Stop C4-26-05, Baltimore, Maryland 21244-1850.

Approval Date: 5/10/2022

STATE PLAN UNDER TITLE XIX OF THE SOCIAL SECURITY ACT

State	WASHINGTON

POLICY AND METHODS USED IN ESTABLISHING PAYMENT RATES FOR EACH OF THE OTHER TYPES OF CARE OR SERVICE LISTED IN SECTION 1905(A) OF THE ACT THAT IS INCLUDED IN THE PROGRAM UNDER THE PLAN.

- XXIV. Payment for items and services furnished in connection with client participation in qualifying clinical trials
 - A. Maximum allowable fees are established and updated using the Resource Based Relative Value Scale (RBRVS) methodology as adopted in the Medicare Fee Schedule Data Base (MFSDB). In this methodology, under WAC 182-531-1850, the agency uses CMS-established relative value units (RVU) multiplied by both the Geographic Practice Cost Indices (GPCI) for Washington State (supplied by the Federal Register) and the conversion factors specific to Washington. The agency's conversion factor that is annually adjusted based on utilization and budget neutrality from year-to-year. For the current conversion factor, and further description, see Supplement 3 to Attachment 4.19-B.
 - B. When no MFSDB RVU exists, some of the codes are reimbursed using flat fee (based upon market value, other state's fees, budget impacts, etc.), acquisition cost (the cost of the actual item being billed), Medicare Laboratory Fee Schedule, ASP (106% of ASP), and/or Point of Sale (POS) actual acquisition cost (AAC).

Except as otherwise noted in the plan, fee schedule rates are the same for both governmental and private providers of items and services furnished in connection with participation in a qualified clinical trial. See 4.19-B I, General, #G for the agency's website where the fee schedules are published.

Approval Date: <u>5/10/2022</u> Effective Date: <u>1/1/2022</u>